Gaussian Boson Samplers are photonic quantum devices with the potential to perform intractable tasks for classical systems. As with other near-term quantum technologies, an outstanding challenge is to identify specific problems of practical interest where these devices can prove useful. Here, we show that Gaussian Boson Samplers can be used to predict molecular docking configurations, a central problem for pharmaceutical drug design. We develop an approach where the problem is reduced to finding the maximum weighted clique in a graph, and show that Gaussian Boson Samplers can be programmed to sample large-weight cliques, i.e., stable docking configurations, with high probability, even with photon losses. We also describe how outputs from the device can be used to enhance the performance of classical algorithms. To benchmark our approach, we predict the binding mode of a ligand to the tumor necrosis factor-αconverting enzyme, a target linked to immune system diseases and cancer.

Molecular docking with Gaussian Boson Sampling / Banchi L.; Fingerhuth M.; Babej T.; Ing C.; Arrazola J.M.. - In: SCIENCE ADVANCES. - ISSN 2375-2548. - ELETTRONICO. - 6:(2020), pp. 0-0. [10.1126/sciadv.aax1950]

Molecular docking with Gaussian Boson Sampling

Banchi L.
;
2020

Abstract

Gaussian Boson Samplers are photonic quantum devices with the potential to perform intractable tasks for classical systems. As with other near-term quantum technologies, an outstanding challenge is to identify specific problems of practical interest where these devices can prove useful. Here, we show that Gaussian Boson Samplers can be used to predict molecular docking configurations, a central problem for pharmaceutical drug design. We develop an approach where the problem is reduced to finding the maximum weighted clique in a graph, and show that Gaussian Boson Samplers can be programmed to sample large-weight cliques, i.e., stable docking configurations, with high probability, even with photon losses. We also describe how outputs from the device can be used to enhance the performance of classical algorithms. To benchmark our approach, we predict the binding mode of a ligand to the tumor necrosis factor-αconverting enzyme, a target linked to immune system diseases and cancer.
2020
6
0
0
Goal 9: Industry, Innovation, and Infrastructure
Banchi L.; Fingerhuth M.; Babej T.; Ing C.; Arrazola J.M.
File in questo prodotto:
File Dimensione Formato  
sciadv.aax1950-1.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 594.45 kB
Formato Adobe PDF
594.45 kB Adobe PDF
sciadv.aax1950(1).pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 594.41 kB
Formato Adobe PDF
594.41 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1210395
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 66
  • ???jsp.display-item.citation.isi??? 66
social impact